BMY
Bristol-Myers Squibb Company · Healthcare · Drug Manufacturers - General
Momentum-inputs (vergelijkbare managers):
breedte van houders +4.3% ·
aandelenstroom +1.6% ·
netto nieuwe posities +4.2%
· formule
Brede accumulatie: stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 2.35M | $122.19M | n/a | n/a |
| Q2 2026 | 174 | +1 | 1.33B | $76.64B | +6 | −4 |
| Q1 2026 | 175 | +1 | 1.27B | $76.90B | +4 | −4 |
| Q4 2025 | 173 | +1 | 1.36B | $73.29B | +2 | n/a |
| Q3 2025 | 26 | 0 | 840.35M | $37.89B | n/a | −1 |
| Q2 2025 | 24 | +1 | 649.62M | $30.06B | +2 | −1 |
| Q1 2025 | 20 | 0 | 256.22M | $15.62B | +1 | −1 |
| Q4 2024 | 20 | -1 | 253.42M | $14.33B | n/a | −1 |
| Q3 2024 | 20 | +1 | 169.93M | $8.78B | +1 | n/a |
| Q2 2024 | 19 | n/a | 159.17M | $6.60B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 194.93M | n/a | $9.02B | 0.1% | n/c | 1 | SEC ↗ ×7 |
| 2 | BlackRock ✦ (passief) | 172.23M | n/a | $7.97B | 0.2% | n/c | 1 | SEC ↗ ×22 |
| 3 | State Street Global Advisors ✦ (passief) | 94.74M | -0.1% | $4.39B | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passief) | 46.18M | +1.6% | $2.13B | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passief) | 33.57M | +0.6% | $1.55B | 0.2% | ▲ Add | 5 | SEC ↗ |
| 6 | Wellington Management ✦ | 25.82M | +8.8% | $1.20B | 0.2% | ▲ Add | 5 | SEC ↗ ×7 |
| 7 | PRIMECAP Management ✦ | 22.94M | -0.1% | $1.06B | 0.8% | ▼ Trim | 5 | SEC ↗ |
| 8 | Fidelity (FMR) ✦ | 16.23M | n/a | $751.20M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 9 | Arrowstreet Capital ✦ | 11.31M | +428.5% | $523.60M | 0.4% | ▲ Add | 5 | SEC ↗ |
| 10 | Dodge & Cox ✦ | 8.44M | -35.2% | $390.54M | 0.2% | ▼ Trim | 5 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 7.27M | +25.6% | $336.70M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 12 | AQR Capital Management ✦ | 6.07M | +1.7% | $280.67M | 0.2% | ▲ Add | 5 | SEC ↗ ×7 |
| 13 | Renaissance Technologies ✦ | 3.48M | +67.8% | $161.14M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 2.70M | +15.5% | $125.16M | 0.5% | ▲ Add | 5 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 914.14K | +182.9% | $40.68M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 16 | Two Sigma Investments ✦ | 864.76K | +203.9% | $40.03M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 607.99K | +104.7% | $28.14M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 518.22K | -31.7% | $23.99M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 19 | Millennium Management ✦ | 264.35K | -52.3% | $12.24M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 226.98K | +2.8% | $10.51M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 21 | Adage Capital Partners ✦ | 195.96K | -90.0% | $9.07M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 22 | GAMCO Investors ✦ | 102.10K | +2.8% | $4.73M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 23 | Tweedy, Browne ✦ | 7.18K | Nieuw | $332,547 | 0.0% | New | 1 | SEC ↗ |
| 24 | Marshall Wace ✦ | 4.76K | Nieuw | $220,572 | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Tweedy, Browne | $332,547 | 0.0% |
| Marshall Wace | $220,572 | 0.0% |
Verlaten
| Harris Associates (Oakmark) | $731,880 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 6.60K aandelen, $400 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 6.25K aand · $403,498
Officer · 500 aand · $33,750
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie